ORIGINAL ARTICLE Endovascular Therapy for Acute Stroke with a Large Ischemic Region Shinichi Yoshimura, Nobuyuki Sakai, Hiroshi Yamagami, et al N Engl J Med February 9, 2022DOI: 10.1056/NEJMoa2118191 Abstract BACKGROUND Endovascular therapy for acute ischemic stroke is generally avoided when the infarction is large, but the effect of endovascular therapy with medical care as compared with medical care alone for large strokes has not been well studie...

ORIGINAL ARTICLE Effectiveness of the BNT162b2 Vaccine after Recovery from Covid-19 Ariel Hammerman, Ruslan Sergienko, Michael Friger, et al N Engl J Med February 16, 2022DOI: 10.1056/NEJMoa2119497 Abstract BACKGROUND The risk of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) decreases substantially among patients who have recovered from coronavirus disease 2019 (Covid-19). However, it is unknown how long protective immunity ...

ARTICLES|ONLINE FIRST Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial Benjamin A Fisher, Tonny Veenith, Daniel Slade, et al Lancet Respir Med Published:December 16, 2021DOI:https://doi.org/10.1016/S2213-2600(21)00460-4 Summary Background Dysregulated inflammation is associated with poor outcomes...

CORRESPONDENCE Effectiveness of Homologous or Heterologous Covid-19 Boosters in Veterans Florian B. Mayr, Victor B. Talisa, Obaid Shaikh, et al N Engl J Med February 9, 2022DOI: 10.1056/NEJMc2200415 TO THE EDITOR: Vaccine effectiveness against coronavirus disease 2019 (Covid-19) wanes over time, and boosters are now recommended for residents of the United States starting at the age of 12 years.1 Clinical trials have shown that receipt of a booster that...

ARTICLES| VOLUME 399, ISSUE 10325, P656-664, FEBRUARY 12, 2022 A three-step support strategy for relatives of patients dying in the intensive care unit: a cluster randomised trial Nancy Kentish-Barnes, Sylvie Chevret, Sandrine Valade, et al Lancet 2022; 399: 656-664 Summary Background In relatives of patients dying in intensive care units (ICUs), inadequate team support can increase the prevalence of prolonged grief and other psychological...

ONLINE FIRST (FREE ACCESS) LATEST ARTICLES OPEN ACCESS ~ Consensus and Expert RecommendationBasic ultrasound head-to-toe skills for intensivists in the general and neuro intensive care unit population: consensus and expert recommendations of the European Society of Intensive Care MedicineRobba C. et al. Individualised versus conventional glucose control in critically-ill patients: the CONTROLING study—a randomized clinical trialBohé J. et al. OriginalDexametha...

ORIGINAL ARTICLE Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S Jerald Sadoff, Glenda Gray, An Vandebosch, et al N Engl J Med February 9, 2022DOI: 10.1056/NEJMoa2117608 Abstract BACKGROUND The Ad26.COV2.S vaccine was highly effective against severe–critical coronavirus disease 2019 (Covid-19), hospitalization, and death in the primary phase 3 efficacy analysis. METHODS We conducted the final analysis in the double-blind phase of o...

Research Letter December 30, 2021 Characteristics and Outcomes of Hospitalized Patients in South Africa During the COVID-19 Omicron Wave Compared With Previous Waves Caroline Maslo, Richard Friedland, Mande Toubkin, et al JAMA. Published online December 30, 2021. doi:10.1001/jama.2021.24868 On November 24, 2021, a SARS-CoV-2 variant of concern, Omicron (B.1.1.529), was identified in South Africa as responsible ...

ORIGINAL ARTICLE Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 Jennifer Hammond, Heidi Leister-Tebbe, Annie Gardner, et al N Engl J Med February 16, 2022DOI: 10.1056/NEJMoa2118542 Abstract BACKGROUND Nirmatrelvir is an orally administered severe acute respiratory syndrome coronavirus 2 main protease (Mpro) inhibitor with potent pan–human-coronavirus activity in vitro. METHODS We conducted a phase 2–3 double-blind, randomized...

ORIGINAL ARTICLE Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico Lisa M. Dunkle, Karen L. Kotloff, Cynthia L. Gay, et al N Engl J Med 2022; 386:531-543DOI: 10.1056/NEJMoa2116185 Abstract BACKGROUND NVX-CoV2373 is an adjuvanted, recombinant spike protein nanoparticle vaccine that was shown to have clinical efficacy for the prevention of coronavirus disease 2019 (Covid-19) in phase 2b–3 trials in the United Kingdom and South Af...